Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;19(11):1381-8.
doi: 10.1038/nm.3369. Epub 2013 Oct 7.

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

Christopher J Lord  1 , Alan Ashworth
Affiliations
Review

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

Christopher J Lord et al. Nat Med. 2013 Nov.

Abstract

Synthetic lethality provides a potential mechanistic framework for the therapeutic targeting of genetic and functional deficiencies in cancers and is now being explored widely. The first clinical exemplification of synthetic lethality in cancer has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of cancers with defects in the BRCA1 or BRCA2 tumor suppressor proteins, which are involved in the repair of DNA damage. Although this approach has shown promise, multiple potential resistance mechanisms have been identified. In this Perspective, we discuss these mechanisms and their relevance to the development of selective therapies for BRCA-deficient cancers.

PubMed Disclaimer

References

    1. Cancer Cell. 2011 May 17;19(5):664-78 - PubMed
    1. Cancer Res. 2012 Apr 1;72(7):1608-13 - PubMed
    1. Cancer Res. 2011 Apr 1;71(7):2632-42 - PubMed
    1. Genetics. 1946 May;31:269-90 - PubMed
    1. J Biol Chem. 2012 Feb 3;287(6):4198-210 - PubMed

Publication types

MeSH terms

Substances